Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Advanced Drainage Systems Inc (WMS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Advanced Drainage Systems Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Advanced Drainage Systems Inc trades at $147.16 (market cap $11.57B). The key difference: Advanced Drainage Systems Inc is the larger of the two by market cap, and Advanced Drainage Systems Inc pays a 0.53% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | WMS | |
|---|---|---|
Market Cap | $8.04B | $11.57B |
Sector | Health | Industrials |
52-Week High | $339.75 | $175.38 |
52-Week Low | $241.71 | $110.89 |
Enterprise Value | $7.85B | $13.14B |
Dividend Yield | — | 0.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
WMS trades at $147.62, down 1.89% on the day, with a bullish technical signal and strong fundamentals including a 24.02% ROE and consistent earnings beats. Recent news includes a dividend increase and investor day, while cash flow dipped in 2025 but is projected to recover. The stock shows robust profitability with a 13.98% net margin and trades below the consensus price target of $184.43.
Outlook is positive with analyst support and operational strength, but risks include a high P/E of 27.09 and mixed sentiment from recent Strong Sell ratings. Upside potential exists if earnings momentum continues, though investors should monitor debt levels and competitive pressures in the water management sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Advanced Drainage Systems Inc
Advanced Drainage Systems Inc is engaged in designing, manufacturing, and marketing thermoplastic corrugated pipe and related water management products in North and South America, and Europe. The company's operating segment includes Pipe
Read more on WMS →
